#United States #Northridge #Insulin Delivery #Diabetes Technology #MiniMed

MiniMed's Reported Financial Highlights for Q1 FY2027

On September 1, 2026, MiniMed (Nasdaq: MMED), a prominent player in diabetes technology, announced stellar financial results for the first quarter (Q1) of fiscal year 2027, which concluded on July 31, 2026. The company achieved net sales of $843 million, representing a 17% growth compared to the previous year and a solid 16% organic growth. Notably, U.S. net sales growth saw an acceleration at 13%, alongside a remarkable 18% growth in international sales.

Accelerated U.S. Growth

MiniMed’s CEO, Que Dallara, expressed enthusiasm about the company’s acceleration in the U.S. market, noting that the launch of their MiniMed Flex™ product has successfully attracted new patients and significantly boosted account growth. This highlights MiniMed's strategy to strengthen its position in the automated insulin delivery space, further contributing to shareholder value.

Market Expansion and Product Innovations

In the first quarter, international net sales hit $603 million, marking an 18.1% increase. This growth was bolstered by the expansion of Simplera™ capacity and the rollout of the Instinct sensor by Abbott. In addition, MiniMed reported selling approximately 34,000 new pumps during the quarter, a commendable 7.7% year-on-year increase, driven primarily by the MiniMed Flex™ and new sensor introductions.

Moreover, the worldwide Continuous Glucose Monitoring (CGM) attachment rate reached 69%, an increase of about 100 basis points from the previous quarter.

Notable Q1 Developments

Several key developments characterized Q1 2027 for MiniMed:

• - The MiniMed Flex™ was successfully launched in the U.S. with enhanced coverage for Medicare and Medicare Advantage beneficiaries.
• - The MiniMed™ 780G system and MiniMed Go™ with the Instinct Go sensor were launched in Europe.
• - MiniMed Fit™, a revolutionary patch pump, has already been submitted to the U.S. FDA for approval, with plans for a full U.S. launch anticipated for the summer of 2027.

Future Growth Expectations

As MiniMed looks forward, there has been a notable raise in their organic revenue growth guidance to approximately 10.5% for FY27, up from an earlier estimate of 10%. The adjusted EBITDA margin is expected to remain around 16%.

Conference Call and Investor Engagement

On the same day of the announcement, MiniMed hosted a conference call to discuss these strong financial results, available on their investor relations website. They also provided an investor presentation for more detailed analysis of the Q1 results.

Conclusion

MiniMed continues to demonstrate its leadership in the diabetes technology space, aided by innovative products that meet the needs of patients. As the company expands its pipeline and enhances its offering through strategic launches, their commitment to creating a seamless experience for individuals with diabetes remains unwavering. The futures of MiniMed and its stakeholders appear bright as they work towards ongoing advancement in diabetes management technology.